Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
06/2003
06/05/2003WO2003045917A2 Ccr-3 receptor antagonists vii
06/05/2003WO2003045913A1 Benzamide derivatives, processes for their preparation, and their pharmaceutical use
06/05/2003WO2003045903A1 Hydroxyethylene compounds with asp2 inhibitory activity
06/05/2003WO2003045902A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/05/2003WO2003045582A1 Metallic structures incorporating bioactive materials and methods for creating the same
06/05/2003WO2003045439A1 Genetic remedies for neurodegenerative diseases
06/05/2003WO2003045438A1 Increasing electro-gene transfer of nucleic acid molecules into host tissue
06/05/2003WO2003045434A2 Endothelin antagonists ina method and composition for potentiating an opiate analgesic
06/05/2003WO2003045429A2 Anti-t cell immunotoxin fusion protein and its therapeutic use
06/05/2003WO2003045426A1 T-cell epitodes in carboxypeptidase g2
06/05/2003WO2003045424A1 Methods of compositions for normalizing lipid levels in mammalian tissues
06/05/2003WO2003045419A1 Injection solution comprising an lhrh antagonist
06/05/2003WO2003045414A2 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
06/05/2003WO2003045404A2 Treatment and diagnosis of diseases associated with adverse levels of zinc, cadmium and calcium
06/05/2003WO2003045403A1 Method of treating halitosis
06/05/2003WO2003045393A1 Piperazine derivatives for use as ccr-3 receptor antagonists in the treatment of asthma
06/05/2003WO2003045388A1 Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
06/05/2003WO2003045386A1 Benzothiazole derivatives
06/05/2003WO2003045384A1 Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of neurodegenerative diseases
06/05/2003WO2003045383A1 Use of ppar activators for the treatment of pulmonary fibrosis
06/05/2003WO2003045378A1 Amino acid derivatives useful for the treatment of alzheimer's disease
06/05/2003WO2003045373A1 Use of propionyl l-carnitine or one of its pharmacologically acceptable salts for the preparation of a medicine for the treatment of la peyronie's disease
06/05/2003WO2003045372A1 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
06/05/2003WO2003045368A1 Pharmaceutical composition comprising a combination of metformin and a 4-oxobutanoic acid, and the use thereof for treating diabetes
06/05/2003WO2003045367A1 Angiogenesis inhibitor
06/05/2003WO2003045355A1 Pharmaceutical compositions comprising metformine and glibenclamide for the treatment of type-ii diabetes mellitus
06/05/2003WO2003045333A2 Treatment of hyperproliferative diseases using active vitamin d analogues
06/05/2003WO2003045319A2 Targeted therapeutics and uses thereof
06/05/2003WO2003045318A2 Manipulation of cytokine levels using cd83 gene products
06/05/2003WO2003045313A2 2-aminoquinoline compounds
06/05/2003WO2003045272A2 ORAL IMMUNOSTIMULATION OF MAMMALS, BIRDS, FISH AND REPTILES FROM (1-4) LINKED ß-D-MANNURONIC ACID
06/05/2003WO2003045228A2 Methods for treating autoimmune disorders, and reagents related thereto
06/05/2003WO2003045136A1 Disruption of the prostaglandin e synthase 2 gene
06/05/2003WO2003035043A3 Pharmaceutical formulation comprising more than 15% tamoxifen
06/05/2003WO2003029418A3 Proliferation and differentiation of stem cells using extracellular matrix and other molecules
06/05/2003WO2003020241A9 Functional powders for oral delivery
06/05/2003WO2003008430A3 Porphyrin derivatives for photodynamic therapy
06/05/2003WO2002102306A3 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy
06/05/2003WO2002074924A3 Method for measuring serine palmitoyltransferase in mammalian tissue and use thereof
06/05/2003WO2002060932A3 A serpin in bifidobacteria
06/05/2003WO2002048351A3 A method for in vitro molecular evolution of protein function
06/05/2003WO2002048124A3 Piperazine derivatives
06/05/2003WO2002046230A3 G-protein coupled receptors
06/05/2003WO2002042330A3 Cystoskeleton-associated proteins
06/05/2003WO2002036075A3 Small molecule compositions for binding to hsp90
06/05/2003US20030106085 Disruption of the prostaglandin E synthase 2 gene
06/05/2003US20030106082 Transgenic stem cells, formed by dissociating blastomeres, are cultured, impregnated within surrogate; animals models; gene therapy
06/05/2003US20030105359 Having good thermal stability and/or solubility characterisitics
06/05/2003US20030105336 Pyrazole derivatives, their preparation and their use in pharmaceuticals
06/05/2003US20030105329 Process for the production of piperidine derivatives
06/05/2003US20030105318 G-protein transmembrane domain; protein synthesis inhibitor; neurotransmitter
06/05/2003US20030105311 Oligonucleotides having A-DNA form and B-DNA form conformational geometry
06/05/2003US20030105293 Human circulating cytokine cc-1
06/05/2003US20030105292 Continously induced g-protein coupled receptors; membrane binding assays
06/05/2003US20030105285 Odorant receptors
06/05/2003US20030105168 Composition comprising ubiquinone
06/05/2003US20030105165 Gap junctions and EDHF
06/05/2003US20030105161 Analgesics; antiinflamamtory agents
06/05/2003US20030105151 Anticancer agents; antiinflammatory agents; autoimmune diseases; rheumatic diseases
06/05/2003US20030105148 Selective estrogen receptor modulators
06/05/2003US20030105144 Celecoxib dissolving in polyethylene glycol; antiinflammatory agents, osteoporosis, respiratory system disorders, antitumor agents, analgesics
06/05/2003US20030105142 Amide derivatives useful as inhibitors of the production of cytokines
06/05/2003US20030105139 Indole derivatives as 5-HT receptor antagonist
06/05/2003US20030105133 4-Substituted piperidine analogs and their use as subtype selective NMDA receptor, antagonists
06/05/2003US20030105129 Chemical compounds
06/05/2003US20030105125 Tropane analogs and methods for inhibition of monoamine transport
06/05/2003US20030105123 For therapy of respiratory system disorders
06/05/2003US20030105122 Compounds for enhancing chemotherapy
06/05/2003US20030105114 Methods of treatment and kits comprising a growth hormone secretagogue
06/05/2003US20030105113 Enantiomers of 1-[ (4-chlorophenyl) phenylmethyl ] -4-[ (4-methylphenyl) sulfonyl ] piperazine
06/05/2003US20030105112 Enantiomers of 1-[(4-chlorophenyl) phenylmethyl]-4-[(4-methylphenyl) sulfonyl] piperazine
06/05/2003US20030105110 Novel compounds
06/05/2003US20030105107 Novel lipoic acid heterocyclic or benzene derivatives, preparation and use thereof as medicines
06/05/2003US20030105106 5-HT receptor ligands and uses thereof
06/05/2003US20030105105 As anticoagulant agents for therapy and prophylaxis of thromboembolic disorders
06/05/2003US20030105104 Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy
06/05/2003US20030105102 Oxo-substituted compounds, process of making, and compositions and methods for inhibiting PARP activity
06/05/2003US20030105096 Serotonin transport inhibitors
06/05/2003US20030105095 4'-Methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor
06/05/2003US20030105094 For therapy of metabolic disorder, an eating disorder or diabetes
06/05/2003US20030105092 Prevention of loss and restoration of bone mass by certain prostaglandin agonists
06/05/2003US20030105090 For therapy of cancer, diabetes
06/05/2003US20030105088 Thiol-based NAALADase inhibitors
06/05/2003US20030105087 New polycyclic azaindole compounds
06/05/2003US20030105085 Antagonists of MCP-1 function and methods of use thereof
06/05/2003US20030105084 Compound which inhibit the release of inflammatory cytokines
06/05/2003US20030105083 Drug combination for the treatment of depression and related disorders comprising mirtazapine
06/05/2003US20030105081 Heterocyclic compounds as ligands of the GABAA receptor
06/05/2003US20030105079 Novel phenylalkyl diamine and amide analogs
06/05/2003US20030105075 Hymenialdisine or derivatives thereof in the manufacture of medicaments
06/05/2003US20030105073 For therapy of cancer, inflammatory disorders, autoimmune disorders, psoriatic disorders and viral disorders
06/05/2003US20030105050 Disorders caused by overproduction of collagen fibres, for example, liver cirrhosis, kidney, liver and heart fibrosis, scleroderma, hypertrophic scars and keloids
06/05/2003US20030105031 Administering therapeutically effective amount of one or more flavonoids and carrier for therapy of reactive and inflammatory dermatoses
06/05/2003US20030105027 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
06/05/2003US20030105025 Tri-and tetrapeptides having antiangiogenic activity
06/05/2003US20030105024 Methods and reagents for discovering and using mammalian melanocortin receptor agonists and antagonists to modulate feeding behavior in animals
06/05/2003US20030105021 Using peptide comprising a chain of 7 to 17 contiguous amino acids derived from region of human TNF- alpha from Ser100 to Glu116 or from region of mouse TNF- alpha from Ser99 to Glu115 for manufacture of a medicament for oedema
06/05/2003US20030104992 A cyclic polypeptides; immunosuppressive anti-inflammatory activity, inhibiting antigen-induced inflammatory cell infiltration
06/05/2003US20030104980 Treating sexual desire disorders with flibanserin
06/05/2003US20030104975 Useful for identification of compounds that induce or inhibit the recruitment of the p160 family cofactors, especially TIF-2 and/ or SRCs cofactors (Translation initiation factor-2 and steroid receptor cofactors)
1 ... 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 ... 1564